Aims Current data concerning the influence of X-ray contrast media on the incidence of thrombotic complications in interventional cardiology are controversial. The effect of ionic contrast media on acute (c72 h) and subacute (c30 days) stent thrombosis has not been investigated.
Introduction
Non-ionic X-ray contrast media are more favourable in terms of side effects than ionic contrast media. Consequently, in many interventional centres, the former are preferred as radiodiagnostic agents in interventional cardiology [1] [2] [3] [4] [5] . Contrast media have various effects on the coagulation cascade, on fibrinolysis and plateletfunction [6] . Thrombotic complications represent a major risk and are associated with percutaneous transluminal coronary angioplasty, especially in the setting of an acute coronary syndrome [7] . They are the leading cause of morbidity (myocardial infarction, intensive care monitoring) and mortality after coronary angioplasty [8] . In several randomized and non-randomized trials, the use of the ionic contrast medium Ioxaglate was associated with a reduction in thrombotic events after coronary angioplasty [8] [9] [10] [11] [12] [13] . In a study of 500 patients, Piessens et al. demonstrated a difference in the incidence of coronary intraluminal filling defects, of 3·2% and 7·2% after coronary angioplasty in patients treated with Ioxaglate and Iohexol, respectively [8] . Comparing nonionic vs ionic contrast media in patients at high risk for thrombosis, i.e. unstable angina, acute myocardial infarction, post infarct angina, Grines et al. found evidence of a periprocedural decrease in intracoronary blood flow in 17·8% and 8·1% of patients, respectively [11] . In addition, the incidence of post-interventional ischaemic events as well as the need for revascularization was found to be significantly lower in the Ioxaglate arm of the study [11] . It could be demonstrated that the risk of acute closure and the rate of bail-out coronary stenting was lower with Ioxaglate than with a non-ionic agent [13] . In contrast, a recent trial by Schräder et al. showed that the incidence of major clinical events after coronary interventions was not reduced following Ioxaglate [14] . In summary, there are conflicting data concerning the use of Ioxaglate in coronary interventions. Since an intracoronary stent offers additional thrombotic stimulus it might be expected that the use of ionic contrast Correspondence: Bruno Scheller, MD, Innere Medizin III, Universitätskliniken des Saarlandes, D 66421 Homburg/Saar, Germany media would be similarly beneficial. So far, there are no large trials on the effects of various contrast media in the setting of coronary stenting. The objective of this prospective, controlled study was to compare the effect of different contrast media on the outcome after coronary stenting.
Methods

Study design
In a prospective design, we enrolled all patients undergoing angioplasty with intracoronary stent placement over an inclusion period of 4·5 years. Multivessel intervention was the only exclusion criterion. A total of n=3990 consecutive patients were included.
After obtaining written informed consent for the procedure, the patients were allocated randomly to one of our two cathlab rooms. Both rooms have the same technical equipment (biplane Philips machines). We performed diagnostic coronary angiography, generally using non-ionic contrast media. For the interventional procedure, the patients received either non-ionic contrast media (group I) or Ioxaglate (group II) depending on the daily availability in the allocated room. Nonionic contrast media (group I) consisted of 3% Iobitridol, 18% Iomeprol, 8% Iopamidol, 27% Iopromide, 39% Ioversol and 5% Iodixanol. Table 1 shows the physical properties of the respective substances. Dimeric Ioxaglate served as an ionic contrast medium (group II). The contrast medium was not blinded for the operator.
Cardiac catheterization was carried out through the right or left femoral artery. All patients received 250 mg aspirin and heparin intravenously in ranging dosages with a target activated clotting time of 250-350 s. A balloon-to-vessel ratio of 1·1-1·2 was selected. Different stent types were used (GFX 41·7%, MultiLink/Duet 19·6%, Palmaz-Schatz 11·4%, Cone 6·6%, Tensum 6·2%, others 14·5%). All patients had adjunctive therapy with aspirin 100-320 mg and ticlopidine 500 mg daily for 4 weeks following stent placement.
Any side effect secondary to contrast media injection was documented. Side effects were defined as any change in the patient's status following contrast medium application, even when only mild symptoms occurred (e.g. mild cough, slight skin reaction). The diagnosis of a side effect attributable to the contrast agent was left to the clinical judgment of the interventional cardiologist performing the procedure.
End-points
The rate of acute and subacute stent occlusion served as a primary end-point. Stent occlusion was defined as angiographically proven total occlusion (TIMI flow <2) or flow limiting thrombus formation in stent within 72 h (acute stent occlusion) or 30 days (subacute stent occlusion) after initially successful stenting. Indications for repeat angiography included: recurrent angina pectoris or evidence of ischaemia on non-invasive tests. Secondary end-points were a binary restenosis rate (diameter stenosis c50%), and a combined clinical end-point consisting of coronary artery bypass grafting, target lesion revascularization, and overall mortality within 12 months.
Statistics
All data are expressed as mean values standard deviation. For the purposes of statistical analysis, classified variables were compared by the chi-square method and continuous variables via Student's t-test, following the determination of normal distribution. Additionally, in a multivariate analysis (logistic regression), the influence of different factors on acute and subacute stent thrombosis were analysed. Statistical analysis was carried out with the software package SPSS 9.0 for Windows.
Results
No significant differences were identified between the two groups of patients with respect to gender, age, the incidence of diabetes mellitus, angina class, the presence of an acute coronary syndrome (unstable angina or acute myocardial infarction), history of contrast media intolerance, left ventricular ejection fraction, severity of coronary artery disease, stented vessel, localization of the lesion, restenotic lesions, angiographic data and (Tables 1 and 2 ). Operators were equally distributed between both groups. Heparin use was slightly higher in group I. Patients with non-ionic contrast media received a higher amount of contrast media ( Table 2) .
The incidence of acute as well as subacute stent occlusion was significantly higher in group I (acute stent occlusion: 1·3% vs 0·3%, P=0·001; subacute stent occlusion: 2·4% vs 0·7%, P=0·001) ( Table 4 ). The incidence of the combined clinical end-point consisting of coronary artery bypass grafting, target lesion revascularization, and overall mortality within 12 months, was significantly reduced by Ioxaglate (22·9% vs 16·3%, P=0·001) ( Table 4 , Figs 1 and 2 ). In the multivariate analysis, non-ionic contrast media were the only independent factors determining acute and subacute stent occlusion ( Table 5 ). The need for reangiography was more frequent in the non-ionic group: 53·5% in group I vs 48·7% in group II within 12 months (P=0·002). The binary restenosis rate was 34·0% and 27·9% in groups I and II, respectively (P=0·003).
The incidence of side effects attributable to the contrast medium was significantly lower in the non-ionic group. The incidence of severe, life-threatening side effects did not differ significantly between either group (Table 4) .
No significant differences between the non-ionic contrast media in group I were found regarding the incidence of the use of ReoPro , restenosis and the combined clinical end-point. The subgroup of 160 
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patients receiving the non-ionic dimer Iodixanol had the highest rate of subacute stent occlusion (5·0%, P=0·015).
Discussion
Platelet activation and aggregation play a key role in the development of acute and subacute stent thrombosis. During coronary angioplasty, the surface expression of platelet activation factors increases significantly [15] and enhanced platelet activity is noted [16] . Coronary stenting results in more significant platelet activation than conventional coronary angioplasty [17] . While non-ionic contrast media cause profound platelet degranulation, a similar effect cannot be induced by ionic contrast media, which indicates that modulation of platelet function is dependent on the type of contrast medium used [18] . Non-ionic contrast agents exhibit significant platelet activating properties in vitro, similar to the effect of thrombin -the most potent substance in platelet activation. In contrast, this effect could not be documented using Ioxaglate [18, 19] . On the other hand, binding of fibrinogen to the GP IIb/IIIa receptor during platelet aggregation is impaired in the presence of contrast media. This effect has been shown to be more pronounced when an ionic contrast medium is used [20] . In contrast to non-ionic contrast media, Ioxaglate is a very potent inhibitor of thrombin generation in plasma [21] . Furthermore, non-ionic contrast media cause a change in the structure of fibrin, leading to impaired thrombolysis [22, 23] . Previous clinical data suggest a benefit from the use of ionic contrast media in patients undergoing coronary angioplasty [8, 9, 11, 13, 24] . Electronmicroscopic demonstration of thrombotic material on catheters and guidewires used during coronary intervention was found to be more significant in cases of non-ionic contrast media administration than ionic contrast media [25, 26] . Angioscopically, the incidence of thrombus formation has been found to be lower with the use of Ioxaglate [12] . The angiographic incidence of intraluminal thrombus formation after coronary angioplasty was reduced by 56% to 90% [8, 9, 24] using the low osmolar ionic contrast medium. In contrast, Schräder et al. found no benefit from Ioxaglate in reducing the incidence of abrupt closures and major adverse cardiac events after coronary intervention. A reason for this might be the significant diversity of the groups: the larger subgroup receiving the non-ionic contrast medium underwent intracoronary stent implantation (31·6% vs 25·7%, P=0·004) [14] . Moreover, the incidence of abrupt closures in both groups were very high (greater than 6%) [14] . In our study, both groups were comparable (Tables 2  and 3) . Although statistically significant, the differences in the volume of contrast agents and in heparin dose are low. Acute and subacute stent thrombosis rates were significantly decreased using the ionic contrast medium. This reduction is more pronounced than the previously demonstrated decrease in thrombotic events in coronary angioplasty alone [8] [9] [10] [11] 24] . A possible explanation is that because of the introduction of a foreign body with procoagulant properties such as a stent, the significant advantage of Ioxaglate becomes more evident. This could be explained by the more pronounced activation of platelets in coronary stenting compared to coronary angioplasty alone [17] . Acute coronary syndrome represents another situation with distinct platelet activation [27] . About one third of our patients had unstable angina or acute myocardial infarction. In this setting, the significant clinical benefit of Ioxaglate during coronary angioplasty alone could be demonstrated [10, 11] . There is controversy concerning the impact of nonionic isoosmolar contrast media. The recently published 
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VIP trial comparing Iodixanol (non-ionic dimer) and Ioxaglate showed no significant differences in cardiac events at the 2-day follow-up (4·7% in the non-ionic group vs 3·9% in the ionic group) [28] . In contrast, the subgroup of patients receiving Iodixanol in our study had the highest rate of subacute stent occlusion (5·0%, P=0·015). Further studies are warranted to clarify this conflict.
So far, there are no data available concerning the long-term effects of contrast media in coronary interventions. In our study, the number of patients developing symptoms consistent with angina within 12 months was lower in the group receiving Ioxaglate, as reflected in the decreased need for repeat angiography. The binary restenosis rate was reduced from 34·0% to 27·9% (P=0·003) and the target lesion revascularization rate was significantly lower (16·6% vs 10·5%, P=0·001) with the use of Ioxaglate. Additionally, the incidence of the combined clinical end-point, consisting of coronary artery bypass grafting, target lesion revascularization and death was significantly reduced in the Ioxaglate group during the whole follow-up period (Fig. 1) . One possible explanation for this finding could be the inhibitory effects of Ioxaglate on thrombin [18] . Thrombin plays an important role in the process of in-stent restenosis due to its mitogenic potential on smooth muscle cells [29] . The increased risk of adverse reactions is a major limitation, restricting the use of ionic contrast media in interventional cardiology. Severe life threatening reactions, however, appear to occur with the same frequency in both compounds [1] [2] [3] [4] [5] 11] . In our study, the incidence of side effects attributable to the contrast medium was significantly lower in the non-ionic group. However, the incidence of any adverse reaction and of severe life threatening reactions was equally distributed among both groups.
Our study is limited by the fact that it was not performed in a double-blinded way. On the other hand, our study is the largest trial on the impact of contrast media in interventional cardiology published so far, and the only one focused on coronary stenting. Another limitation is that patients did not routinely undergo repeat angiography. Reangiography was only performed following recurrent angina pectoris or on evidence of ischaemia on non-invasive testing. Therefore the rate of reangiography within 12 months was only 51%. A prospective randomized trial with respect to restenosis rate in relation to different contrast agents is warranted.
Based on our data and on the findings of recent in vitro and clinical studies, we recommend the use of Ioxaglate in coronary interventions, where platelet activation and aggregation are increased e.g. during acute coronary syndromes, and anticipated stent placement.
